Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2022-06-29 00:00:00 ET · period of report 2022-06-27 · accession 0001209191-22-039819 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-29 | 2022-06-27 | FATE | Powl Brian T. | Chief Commercial Off | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
| D | 2022-06-29 | 2022-06-27 | FATE | Powl Brian T. | Chief Commercial Off | A - Grant | $0.00 | +70.0K | 70.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-27 | A | A | 45,000 | $0.00 | 45,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-27 | A | A | 70,000 | $0.00 | 70,000 | D | $26.25 · — to 2032-06-27 | 70,000 Common Stock | (F2) The option shall vest as to 25% of the underlying shares on June 27, 2023 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. |